MX2023002479A - Nuevas formas de nucleosidos antivirales. - Google Patents
Nuevas formas de nucleosidos antivirales.Info
- Publication number
- MX2023002479A MX2023002479A MX2023002479A MX2023002479A MX2023002479A MX 2023002479 A MX2023002479 A MX 2023002479A MX 2023002479 A MX2023002479 A MX 2023002479A MX 2023002479 A MX2023002479 A MX 2023002479A MX 2023002479 A MX2023002479 A MX 2023002479A
- Authority
- MX
- Mexico
- Prior art keywords
- virus
- cov
- crystalline forms
- equine encephalitis
- sars
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- 239000002777 nucleoside Substances 0.000 title 1
- 125000003835 nucleoside group Chemical group 0.000 title 1
- 241001678559 COVID-19 virus Species 0.000 abstract 2
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 2
- 241000315672 SARS coronavirus Species 0.000 abstract 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 abstract 2
- 241000710951 Western equine encephalitis virus Species 0.000 abstract 2
- 201000009182 Chikungunya Diseases 0.000 abstract 1
- 208000004293 Chikungunya Fever Diseases 0.000 abstract 1
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 abstract 1
- 241001115402 Ebolavirus Species 0.000 abstract 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 241000907316 Zika virus Species 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- HTNPEHXGEKVIHG-ZJTJHKMLSA-N molnupiravir Chemical compound CC(C)C(=O)OC[C@H]1O[C@H](C(O)C1O)N1C=C\C(NC1=O)=N\O HTNPEHXGEKVIHG-ZJTJHKMLSA-N 0.000 abstract 1
- 229940075124 molnupiravir Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 1
- 229940045145 uridine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Las nuevas formas cristalinas de molnupiravir, incluidas las formas cristalinas I y II, que son formas cristalinas de uridina 4-oxima 5'-(2-metilpropanoato), pueden ser útiles como agentes antivirales, específicamente como tratamientos antivirales para infecciones causadas por el Virus de la Encefalitis Equina del Este (EEEV), Virus de la Encefalitis Equina Occidental (WEEV) y Virus de la Encefalitis Equina Venezolana (VEEV), Virus de la Fiebre Chikungunya (CHIK), Virus del Ébola, Virus de la Influenza, Virus Respiratorio Sincitial (RSV), Virus del Zika y Coronavirus, tales como el Coronavirus del Síndrome Respiratorio Agudo Severo (SARS-CoV), el Coronavirus del Síndrome Respiratorio de Oriente Medio (MERS-CoV) y, más recientemente, el SARS-CoV-2 (también conocido como 2019-nCoV).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071132P | 2020-08-27 | 2020-08-27 | |
| US202163160259P | 2021-03-12 | 2021-03-12 | |
| PCT/US2021/048054 WO2022047229A1 (en) | 2020-08-27 | 2021-08-27 | Novel forms of antiviral nucleosides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002479A true MX2023002479A (es) | 2023-07-14 |
Family
ID=80352390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002479A MX2023002479A (es) | 2020-08-27 | 2021-08-27 | Nuevas formas de nucleosidos antivirales. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240025938A1 (es) |
| EP (1) | EP4203970A1 (es) |
| CA (1) | CA3191082A1 (es) |
| CL (1) | CL2023000557A1 (es) |
| MX (1) | MX2023002479A (es) |
| WO (1) | WO2022047229A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11702440B2 (en) * | 2020-12-10 | 2023-07-18 | Optimus Drugs Private Limited | Pharmaceutical polymorphs of Molnupiravir |
| WO2023106964A1 (ru) * | 2021-12-09 | 2023-06-15 | Общество С Ограниченной Ответственностью "Промомед Рус" | Новая кристаллическая форма [(2н,38,4к,5к)-3,4-дигидрокси-5-[4- (гидроксиамино)-2-оксопиримидин-1-ил]оксолан-2-ил]метил-2- метилпропаноата |
| WO2023106963A1 (ru) * | 2021-12-09 | 2023-06-15 | Общество С Ограниченной Ответственностью "Промомед Рус" | Новая кристаллическая форма [(2r,3s,4r,5r)-3,4-дигидрокси-5-[4- (гидроксиамино)-2-оксопиримидин-1-ил]оксолан-2-ил]метил-2-метилпропаноата |
| CN115429770B (zh) * | 2022-10-11 | 2023-06-27 | 安徽贝克生物制药有限公司 | 一种稳定性好的莫诺拉韦药物组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112156102B (zh) * | 2015-09-16 | 2023-10-03 | 济南高合医疗科技有限公司 | 一种nuc-1031单一异构体的晶型及其制备方法 |
| AU2018378832B9 (en) * | 2017-12-07 | 2021-05-27 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| GB2611644B (en) * | 2018-03-07 | 2023-07-26 | Univ Emory | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
-
2021
- 2021-08-27 EP EP21862867.5A patent/EP4203970A1/en active Pending
- 2021-08-27 WO PCT/US2021/048054 patent/WO2022047229A1/en unknown
- 2021-08-27 MX MX2023002479A patent/MX2023002479A/es unknown
- 2021-08-27 US US18/042,982 patent/US20240025938A1/en active Pending
- 2021-08-27 CA CA3191082A patent/CA3191082A1/en active Pending
-
2023
- 2023-02-24 CL CL2023000557A patent/CL2023000557A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240025938A1 (en) | 2024-01-25 |
| CA3191082A1 (en) | 2022-03-03 |
| EP4203970A1 (en) | 2023-07-05 |
| CL2023000557A1 (es) | 2023-12-01 |
| WO2022047229A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002479A (es) | Nuevas formas de nucleosidos antivirales. | |
| EA202092117A1 (ru) | Терапевтические композиции 4'-галогенсодержащих нуклеотидов и нуклеозидов и их применение | |
| WO2022251663A3 (en) | Novel universal anti-rna virus agents | |
| WO2006075993A3 (en) | Nucleoside derivatives for treating hepatitis c virus infection | |
| WO2004043913A3 (en) | Hetero-substituted benzimidazole compounds and antiviral uses thereof | |
| BR0316407A (pt) | Derivados de nucleosìdeo antiviral | |
| Centers for Disease Control and Prevention (CDC | Diagnoses of HIV/AIDS--32 States, 2000-2003 | |
| WO2021262826A3 (en) | 1'-cyano nucleoside analogs and uses thereof | |
| WO2003062255A3 (en) | Sugar modified nucleosides as viral replication inhibitors | |
| WO2004011478A3 (en) | Anti-viral 7-deaza d-nucleosides and uses thereof | |
| WO2009129470A3 (en) | Methods for treating herpes virus infections | |
| TW200745151A (en) | Antiviral nucleosides | |
| WO2006101538A3 (en) | Andrographolide derivatives to treat viral infections | |
| WO2009069095A3 (en) | Antiviral nucleoside compounds | |
| DK1479691T3 (da) | Langvarigt aktive fuionspeptidinhibitorer for HIV infektion | |
| MY148676A (en) | Use of imatinib to treat liver disorders and viral infections | |
| WO2003055896A3 (en) | Anti-viral 7-deaza l-nucleosides | |
| PT88248A (pt) | Processo para a preparacao de composicoes farmaceuticas contendo rnas de cadeia dupla com actividade topica | |
| DK46787A (da) | Antiviralt middel | |
| BR112015031225A2 (pt) | ceifadeira-debulhadora dotada de meios de debulha, meios de preparação e arranjo de limpeza, e método para operar os meios de preparação de ceifadeira | |
| WO2019191026A3 (en) | Methods for the use of 5'-adenosine diphosphate ribose (adpr) | |
| EP0135713A3 (en) | Antiviral combinations | |
| EP2325314A3 (en) | Targeting opposite strand replication intermediates of single-stranded viruses by RNAI | |
| GT200500079AA (es) | Combinaciones de productos activos con propiedades insecticidas (patente fraccionaria no. 1 de la solicitud no. 1 de la solicitud no. pi200500079) | |
| NO20014347D0 (no) | Synergistisk inhibering av viral replikasjon ved langkjedede hydrokarboner og nukleosidanaloger |